Potential treatment for painful side effect of diabetes unveiled by UK researchers
An international team of scientists say that they have a deeper understanding of why diabetics suffer from increased pain and temperature sensitivity, which may lead to new treatment for those side effects of diabetes. Their report appeared in the journal Nature Medicine, May 13.
Painful diabetic neuropathy, which is abnormal and persistent pain experienced by roughly 50% of patients with diabetes, impairs patients' quality of life and affects sleep, mood, mobility, ability to work and self-esteem.
Currently there is no clear understanding of how abnormal glucose metabolism produces heightened pain in diabetics, but this study offers new insights. The team showed that a compound called methylglyoxal (MG), which is produced excessively from glucose in diabetes, is a new culprit in pain discomfort.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze